Topical corticosteroids or dietary elimination are recommended as first-line therapies for eosinophilic esophagitis, but data to directly compare these therapies are scant. We performed a cost utility comparison of topical corticosteroids and the 6-food elimination diet (SFED) in treatment of eosinophilic esophagitis, from the payer perspective.
METHODS:
We used a modified Markov model based on current clinical guidelines, in which transition between states depended on histologic response simulated at the individual cohort-member level. Simulation parameters were defined by systematic review and meta-analysis to determine the base-case estimates and bounds of uncertainty for sensitivity analysis. Metaregression models included adjustment for differences in study and cohort characteristics.
RESULTS:
In the base-case scenario, topical fluticasone was about as effective as SFED but more expensive at a 5-year time horizon ($9261.58 vs $5719.72 per person). SFED was more effective and less expensive than topical fluticasone and topical budesonide in the base-case scenario. Probabilistic sensitivity analysis revealed little uncertainty in relative treatment effectiveness. There was somewhat greater uncertainty in the relative cost of treatments; most simulations found SFED to be less expensive.
CONCLUSIONS:
In a cost utility analysis comparing topical corticosteroids and SFED for first-line treatment of eosinophilic esophagitis, the therapies were similar in effectiveness. SFED was on average less expensive, and more cost effective in most simulations, than topical budesonide and topical fluticasone, from a payer perspective and not accounting for patient-level costs or quality of life.
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E osinophilic esophagitis (EoE) is an emerging clinicopathologic disease. 1 It is clinically characterized by chronic esophageal dysfunction commonly manifesting as dysphagia in adults and adolescents, but with a different spectrum of symptoms in children and infants. 2 The defining pathologic feature of EoE is esophageal eosinophilia, with at least 15 eosinophils per high-power field after an adequate acid-suppression trial and in the absence of other causes of esophageal eosinophilia.
Although there are several therapeutic strategies that have been evaluated for EoE, the strength of evidence supporting the safety and efficacy of these varies widely. 2 However, the 2 medical therapies supported by a broad base of evidence are topical corticosteroids (tCS)
3-27 and 6-food elimination diet (SFED). 18, 23, [28] [29] [30] [31] [32] [33] Esophageal dilation is also used for treatment of strictures or narrowing, [34] [35] [36] [37] [38] [39] [40] but because it does not impact mucosal inflammation 39 it has not been recommended as monotherapy in societal guidelines. 1 Current guidance recommends that either tCS or dietary elimination be used as first-line therapy for EoE. However, because there have been no trials directly comparing these 2 modalities, the comparative effectiveness of tCS and SFED is unknown. In this setting, simulation studies can provide valuable insights regarding the effectiveness and cost of therapeutic strategies and bounds of uncertainty in key parameters. Our aims were (1) to perform a systematic review and metaanalysis of tCS and SFED as therapies for EoE to define simulation model parameters, (2) to perform a simulation comparing tCS and SFED as therapies for initial treatment of EoE, and (3) to estimate bounds of incremental cost and effectiveness of the simulated treatments.
Methods

Model Structure and Assumptions
We performed a cost-utility analysis of tCS compared with SFED in patients with EoE. Cohorts of 300 patients with EoE were chosen to simulate the population. Cohort members were assigned random age and gender proportional to the estimated United States prevalence of EoE. 41 Age was limited to 65 because analysis was from a United States private insurance payer perspective. The clinical treatment algorithm was derived from current management guidelines. Topical steroids were compared with diet elimination therapy as the initial treatment for newly diagnosed EoE cases. Proton pump inhibitor (PPI) therapy was not included because patients were assumed to have failed PPI therapy to establish a diagnosis of EoE. Patients were offered rescue treatment with the alternative therapy if it failed to elicit histologic response. 1 Patients with histologic response but not symptom response were offered dilation as an additional therapy to simulate patients with persistent fibrostenosis after treatment; patients without histologic response to either treatment were offered dilation alone. 1 The cycle length was 3 months and the time horizon was set at 5 years. The health outcome of value was symptom response (extracted as the proportion of full or partial response among all treated study participants, based on the individual study's definition of response).
We used a microsimulation approach with a Markov model structure ( Figure 1A , Supplementary Appendix 2) in which transition probabilities depended on histologic response (defined as an eosinophil count <15 eosinophils/hpf). The distribution of initial eosinophils/hpf was modeled as gamma by fitting initial maximum eosinophil counts from the University of North Carolina EoE Clinicopathologic Database (Supplementary Appendix 3) . In addition to eosinophil count, symptom response and duration of response to dilation were simulated at the individual cohort-member level.
We based the model on current clinical practice and management guidelines, with diagnostic endoscopies at baseline and after initial treatment. 1, 42 If a patient achieved histologic response with tCS, they were maintained on tCS until the time horizon because long-term remission of EoE without continued tCS treatment is uncommon. 43, 44 Maintenance steroids were given at half dose, although a sensitivity analysis was performed for full-dose therapy in maintenance. If a patient achieved histologic response with SFED, they began a food reintroduction protocol that required an additional 6 endoscopies for trigger identification, and then they were maintained on dietary treatment ( Figure 1B) . 23, 29 If a patient failed to achieve histologic response after initial therapy with either tCS or SFED, secondary therapies were tried, although a sensitivity analysis was performed without secondary therapies. Patients who failed tCS received secondary therapy with SFED, and patients who failed SFED received rescue therapy with tCS. If they responded, then they went in to the maintenance pathways as noted previously. If they did not respond then the proportion without prior symptom response underwent endoscopy with dilation for symptomatic treatment. Other second-line or experimental treatments were not included in this model. 45 
Measurement of Effectiveness and Costs
To determine estimates of the effectiveness of therapies for this analysis, we performed a systematic review under the direction of a dedicated library scientist of published manuscripts in peer-reviewed journals describing tCS, SFED, and dilation therapies (Supplementary Appendix 5). 46 Included studies were required to report at least 1 outcome measure of interest and to enroll 2 or more subjects, but the treatment data did not have to be the primary focus of the study. We abstracted multiple measures of the effectiveness and composition of cohorts for these studies. The proportion of patients with prior exposure to therapies was recorded such that meta-regression estimates for both treatment-naive users and patients who failed prior therapy could be generated. We performed random effects meta-regression to estimate the point estimate and standard error for each outcome given a common set of covariates (Supplementary Appendix 1).
Because utilities have not been established for EoE, we estimated that the base-case utility for EoE responding to treatment was equal to utility of treated gastroesophageal reflux disease. 47, 48 To construct a proxy for utility values, the effect of symptomatic control on health-related quality of life was abstracted from adult EoE quality-of-life questionnaire and PedsQL EoE module validation scores. 49, 50 The difference in utility for symptomatic and nonsymptomatic EoE for the present study was calculated by applying the ratio of scores of patients "in remission" and "not in remission" to the utility for treated gastroesophageal reflux disease.
Full-dose topical steroids were assigned base-case costs for fluticasone, 440 mg twice daily for adults (18 years of age or older) and 220 mg twice daily for children. We also performed the base-case analysis for budesonide, 1 mg twice daily for adults and 0.5 mg twice daily for children. Endoscopy costs were assigned from estimates specific to patients with EoE that were stratified between adults and children. 51 Additional costs for endoscopies with dilation were taken as the difference of estimates for esophagogastroduodenoscopy with and without dilation. 52 Costs were in 2015 US dollars based on the November 15 Consumer Price Index category for medical care. 53 Because of the payer perspective of this analysis, costs related to diet changes and missed work for procedures were not included. Discounting of future costs and quality-adjusted life-years (QALYs) was performed at 3% per year.
Sensitivity Analysis
Costs, incremental costs, 5-year effectiveness in QALY, incremental effectiveness, and incremental costeffectiveness ratio per QALY gained were reported for each simulation on a per-cohort-member basis. The willingness-to-pay threshold was set to $50,000/QALY. Probabilistic sensitivity analysis (PSA) was performed for the following model parameters: the probability of symptom response, the mean change in eosinophils for each therapy, the utility of response and nonresponse, and all costs. Model parameters for PSA iterations were derived from the standard error of meta-regression model estimates such that 95% of simulated values fell within the 95% confidence limit of the estimate (Supplementary Appendix 4) . Sensitivity analysis ranges included estimates previously published in other meta-analyses. [54] [55] [56] [57] [58] [59] [60] Simulations of 300-member cohorts were performed with 10,000 PSA iterations. The results of PSA were plotted as a density of incremental cost and incremental effectiveness.
We examined the impact of multiple changes to the model structure. We performed simulations that did not allow dose reduction of steroids following histologic response. We examined scenarios without crossover to the alternate treatment and without crossover or dilation. We performed the base-case simulation stratified by age.
The 95% prediction ellipse, a summary measure expected to contain 95% of simulations within its bounds, and the $50,000 willingness-to-pay threshold, were plotted. The cost-effectiveness acceptability curve was plotted. Simulation and statistical analyses were performed in R 3.2.3 (R Foundation, Vienna, Austria) and TreeAge Pro 2016 (TreeAge Software, Williamstown, MA).
Results
Study Parameters
Systematic review yielded 8 studies with data regarding the effectiveness of SFED 18, 23, [28] [29] [30] [31] [32] [33] and 25 studies 3-27 regarding the effectiveness of tCS from which model parameters for symptom response and change in eosinophil count were derived by meta-regression. Seven studies described dilation in patients with EoE. [34] [35] [36] [37] [38] [39] [40] The mean proportion of patients with symptom response in meta-analysis was 87.3% for SFED, 87.9% for topical budesonide, and 82.3% for topical fluticasone, whereas the proportion with response in eosinophil count <15 eosinophils/hpf was 69.0% for SFED, 76.8% for budesonide, and 70.9% for topical fluticasone. Estimates varied by age and gender, and wide uncertainty around parameter estimates led to wide distributions for sensitivity analysis, with lower response rates than for the overall estimate of meta-analysis (Table 1) .
Incremental Costs and Outcomes
In the base-case scenario, topical fluticasone was slightly less effective than SFED (incremental effectiveness -0.05 QALYs/person) and more expensive ($9262 vs $5720) such that SFED dominated other therapeutic strategies (Table 2) 
Sensitivity Analyses
In PSA, there was little uncertainty regarding relative treatment effectiveness; 95% of simulations varied within a single QALY per patient over 5 years (Figure 2 ). Greater uncertainty was observed for cost, and most scenarios suggested that starting with either steroid was more expensive than starting with SFED. The prediction ellipse for topical budesonide as first-line treatment for EoE was above the willingness-to-pay line but crossed zero in incremental effectiveness (Figure 3 ). Sensitivity analysis that increased the discounting rate for future costs and utilities favored steroids with their cost spread over time versus dietary elimination with a higher initial cost for endoscopies. A higher willingness-to-pay also favored tCS (Figure 4) .
In a scenario in which the dose of steroids could not be reduced 50% after induction, effectiveness was unchanged and the incremental cost for tCS over SFED was increased from $3657 to $8094. In a scenario without crossover to the alternate treatment, SFED was more effective and less expensive than other strategies. In a scenario without crossover treatment or dilation, topical fluticasone and topical budesonide were more effective than SFED but their incremental cost-effectiveness ratios (fluticasone, $180,838; budesonide, $428,428) were well above the willingness to pay. Increased discounting of future costs favored steroids, which spread costs compared with the 7 initial endoscopies required in SFED.
Discussion
In current treatment algorithms for EoE, either tCS or dietary elimination is considered an acceptable first-line treatment. Because there are no data directly examining the comparative effectiveness of these 2 therapies, we performed a cost utility analysis. We found that in the base-case scenario SFED was similarly effective and less expensive than tCS. Most PSA simulations supported this conclusion. Most simulations favored SFED over topical fluticasone, and a still larger majority favored SFED over topical budesonide as a first-line agent. Individual characteristics are reported as the sampling distribution, whereas other simulation parameters are reported as the distribution of means among 300 member cohorts across sensitivity analyses. Incremental effectiveness was minimally sensitive to the modelling assumptions examined. The 95% prediction ellipse for simulations in the base-case scenario spanned only 2 days in incremental effectiveness on a per-person basis. Although this results in a very large incremental cost-effectiveness ratio in some scenarios, the therapies are similarly effective in sensitivity analysis with their differences primarily being in cost. With regard to effectiveness as defined by the diverse scenarios presented, mean effectiveness varied only narrowly between treatments with broad overlap in uncertainty. The literature describing tCS and SFED as treatments for EoE is essentially in equipoise without a randomized comparative study.
This study should be interpreted within the context of limited data on cost-utility research in EoE. Although the economic burden of EoE in the US health system is substantial, 51 there have been no prior cost-utility analyses on first-line therapies for EoE, so we are unable to directly compare our results with other studies. Two other studies, however, have examined costs and effectiveness related to EoE. In one trial, initial treatment with esophageal dilation was compared with esophageal dilation plus tCS, and in subanalyses dilation was believed to be more cost effective. 61 These findings may not generalize to a scenario such as is modeled here, where mucosal therapies alone may obviate dilation in some patients. The other study examined the cost effectiveness of biopsy to diagnose EoE in patients with refractory gastroesophageal reflux disease, finding it was cost effective if the prevalence of EoE was >8%.
48
Our study has several limitations. The results are dependent on our parameter estimates and the methodology of the studies that were reviewed. Patients in the model accrue value based on symptom response and this has an incompletely characterized relationship with mucosal response. 62 Because studies reported symptom improvement in the absence of validated instruments, bias and measurement error may limit interpretation of this analysis. The absence of a disease-specific utility value for EoE also limits this study, although the utility values for response and nonresponse were nondifferential between groups. Although this study suggests SFED could be a cost-effective alternative to tCS, it should not be offered as the only first-line therapy. SFED has been studied only among patients who desire to pursue such therapy. 18, 23, [28] [29] [30] [31] [32] [33] SFED can be expensive and difficult for some patients to undertake. 63 In addition, our study examined costs from a payer perspective and does not take into account costs to the patient, which can be important. For example, dietary elimination is not free to the patient, and costs for specialized foods can be significant. Moreover, implementing a SFED can have a substantial impact on patient quality of life and social behaviors of patients. The payer perspective of this analysis dictates that only costs to an insurer are considered, such that the results of this analysis are not directly applicable to cost-effectiveness for an individual patient. Importantly, the analysis also cannot account for direct and indirect costs, such as time lost from work and travel-related expenditures, incurred by the patient and their caretaker during the serial endoscopies required for food reintroduction. Costeffectiveness from a patient perspective should be the subject of further research. This analysis focuses on patients with EoE defined as peak esophageal eosinophilia following a trial of PPI and this prevents PPI from being studied as a therapy.
This study also has several strengths. The study was performed and reported in accordance with applicable guidelines. 64 Model parameters were estimated through systematic review and meta-analysis of all published manuscripts, mitigating bias in study selection. Use of meta-regression coefficients or moderators for studies' baseline patient characteristics and design features allowed adjustment for differences in study features between treatment types. These are particularly important given the absence of randomized clinical trials of SFED. The simulation incorporates heterogeneity of effects by age in addition to a conservative accounting for probabilistic uncertainty by performing PSA for all model parameters.
Conclusions
This cost utility analysis comparing tCS with SFED for first-line treatment of EoE showed that the therapies were similar in effectiveness, but tCS were more expensive, especially if topical budesonide rather than fluticasone was used. Substantial uncertainty remains and the comparative effectiveness of tCS and SFED for EoE can only be resolved by a randomized clinical trial. However, our data suggest that, on average, when compared with tCS as first-line therapy for EoE, SFED should be about as effective and substantially less expensive from a payer perspective over 5 years.
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